Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia

Hemasphere

by Alfredo Marchetti, Francesca Lazzaroni, Matteo Claudio Da Via', Marta Lionetti, Giulia Maggioni, Alessia Campagna, Denise Ventura, Giorgio A. Croci, Alessio Marella, Akihiro Maeda, Antonio Matera, Emanuele Calvi, Margherita Scopetti, Filippo Viviani, Nicolò Rampi, Davide Bonometti, Elena Benzoni, Manuela Zappa, Sonia Fabris, Marzia Barbieri, Stefania Pioggia, Claudia Leoni, Antony Ricchiuti, Matteo G. D. Porta, Mariarita Sciumè, Francesco Passamonti, Nicola S. Fracchiolla, Niccolò Bolli
October 13, 2026

Bone Marrow Transplantation

Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee

The Medicine Maker

Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next

October 12, 2026
9 min

Nature Cancer

Immune and Cellular Factors Shaping Response to Hypomethylating Agent–Venetoclax Therapy in Acute Myeloid Leukemia

Original Source(s)

Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia

Related Content

Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee

Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance